Many of you have already heard about NDI-034858 from Nimbus Therapeutics, which was first disclosed in August at ACS Chicago 2022, and is now acquired by Takeda Pharmaceutical for $6 billion. It is a potent, allosteric tyrosine kinase 2 (TYK2) inhibitor now in Phase 2 clinical trials with exceptional results as a future drug for treating plaque psoriasis. This drug candidate contains several interesting fragments in its backbone.
We hope these Building Blocks will be the perfect start for your research!
